The world's twelfth VEGF drug will be sold by Takeda
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
Biopharma’s bolt-on bonanza is set to continue
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
